A Phase 1 Study for the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy in Japanese Postmenopausal Women With Estrogen Receptor-Positive And Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (AMEERA-2)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amcenestrant (Primary)
Indications Adenocarcinoma; Advanced breast cancer
Focus Adverse reactions
Acronyms AMEERA-2
Sponsors Sanofi

Most Recent Events

13 Jan 2025 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: Sponsor decision to prematurely stop the study, not linked to any safety concern.)
06 Dec 2024 Planned End Date changed from 29 Nov 2023 to 26 Dec 2024.
21 Dec 2023 Planned End Date changed from 30 Nov 2023 to 29 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight